Research and Clinical Trials
Search Cancer Clinical Trials
Clinical Trials
New Search
| Title | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function (RENAL) |
|---|---|
| Disease/Condition | Phase 1¸ Organ Dysfunction¸ and Other Experimental |
| Description | The purpose of this study is to evaluate the following: * Whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations. * Determine the effect renal impairment has or does not have on the absorption of azacitidine. * Determine if azacitidine is safe and well tolerated in patients with renal function impairment. |
| Eligibility Criteria | To be eligible for this study, patients must meet several criteria, including but not limited to the following: * Patient must be 18 years and older * MDS according to the FAB classification system (RA, RARS, RAEB, RAEB-T, CMML), AML in remission, malignant solid tumor, MM, NHL, or HD. * Patient must have a life expectancy more than or equal to 3 months * Patient must be a nonsmoker or must not have smoked for at least 30 days before the screening visit and agree to abstain from smoking during study participation. |
| Principal Investigator | Sanjay Goel, MD |
| Phone | (718) 904-2488 |
| Contact Email | sgoel@montefiore.org |
| Post Date | 04/01/2008 |
| Protocol Number | 10-09-298/West |
| Status | Recruiting |
| Current Trial Type | Interventional |
